The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
about
Treating Negative Symptoms in Schizophrenia: an UpdateModulatory effects of α7 nAChRs on the immune system and its relevance for CNS disordersnAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.The Protective Effect of Alpha 7 Nicotinic Acetylcholine Receptor Activation on Critical Illness and Its MechanismWhat is the promise of nicotinergic compounds in schizophrenia treatment?1,3-diphenylpropan-1-ones as allosteric modulators of α7 nACh receptors with analgesic and antioxidant properties.PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans.Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging.Activation of Alpha-7 Nicotinic Acetylcholine Receptor Reduces Brain Edema in Mice with Ischemic Stroke and Bone Fracture.Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning.Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness.Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.Reversal of Mecamylamine-Induced Effects in Healthy Subjects by Nicotine Receptor Agonists: Cognitive and (Electro)Physiological Responses.PET Brain imaging of α7-nAChR with [18F]ASEM: Reproducibility, occupancy, receptor density, and changes in schizophrenia.GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.Activation of Central Alpha 7 Nicotinic Acetylcholine Receptor Reverses Suppressed Immune Function of T Lymphocytes and Protects Against Sepsis Lethality.Schizophrenia: synthetic strategies and recent advances in drug design
P2860
Q26744805-76091F69-843D-4E87-81E6-493538F4C517Q26765419-C629AE79-472D-40F1-80D5-03AAC28D35A4Q30362464-D094AD01-608F-4919-9E11-EDCC58C35443Q37604595-71AE7E94-1728-42A0-A32D-BB0EC3C5A952Q38811805-228E6955-8BB1-48F6-9D18-706B0E03B170Q38869450-9BD3902B-5076-4AB3-9F9A-C5C8F17EB3F5Q39000956-D3312341-E023-4479-9E22-B058C5AEDC9BQ39261867-0240E410-421B-4CBE-85FE-71C12AA4E149Q46432309-184767A4-42EB-4AEC-B396-94DA8236710EQ47158626-8B47D4F4-C4A4-41BC-91F3-F0E5F3601029Q47322794-B8554F24-04BE-45AD-9540-B2173E340255Q47857735-7E2D2913-DF17-45E7-9A6C-3ACCF22B448BQ48271174-A274A0AD-348B-4A9C-BB89-AE5D9F5A372CQ51742249-66E09C53-CB86-4EC8-AFE3-ADCA81BA63A9Q53428761-061877FC-A2BC-4666-8E4D-A105855A4AFDQ55434578-69ACC6D0-0766-47DA-9603-12664741A17DQ57393544-E76E5847-7B1E-44EE-ACE1-F374974F98F3
P2860
The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The therapeutic potential of α ...... associated with schizophrenia.
@en
type
label
The therapeutic potential of α ...... associated with schizophrenia.
@en
prefLabel
The therapeutic potential of α ...... associated with schizophrenia.
@en
P2093
P2860
P1433
P1476
The therapeutic potential of α ...... associated with schizophrenia.
@en
P2093
Corinne Beinat
Marco Herrera
Vivian Law
P2860
P2888
P304
P356
10.1007/S40263-015-0260-0
P577
2015-08-05T00:00:00Z